Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LCP1
REST API REST API
Homo sapiens
LCP1 is differentially expressed in 276 experiments: 106 organism parts: bone marrow, lung, ... (104 more);, 254 disease states: normal, prostate carcinoma, ... (252 more);, 110 cell types 492 cell lines 42 compound treatments and 70 other conditions.
Synonyms L-PLASTIN, LC64P, PLS2, CP64
Orthologs Lcp1 (Mus musculus)   Lcp1 (Rattus norvegicus)   LCP1 (Bos taurus)   LCP1 (Danio rerio)   Q5ZLW0_CHICK (Gallus gallus)   ENSCING00000005737 (Ciona intestinalis)   SAC6 (Saccharomyces cerevisiae)   Fim (Drosophila melanogaster)   lcp1 (Xenopus laevis)   LCP1 (Canis familiaris)   (Compare orthologs)
InterPro Term EF-hand, EF_HAND_2, EF_hand_Ca-bd, CH-domain, CAMSAP_CH
Gene Ontology Term cytosol, plasma membrane, protein binding, actin filament, cytoplasm, actin filament bundle assembly, ruffle, cell junction, regulation of intracellular protein transport, identical protein binding, actin cytoskeleton, actin filament binding, calcium ion binding, actin binding, T cell activation involved in immune response, organ regeneration, phagocytic cup, ruffle membrane
UniProt Accession P13796, Q5TBN5, Q5TBN3, B4DUA0
Search EB-eye ENSG00000136167
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (38 experiments)

Factor Value U/D Experiments
SW480
1
3
E-MEXP-1014, E-MTAB-37, E-GEOD-2509, E-GEOD-18005
HL-60
1
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
BT474
2
E-MTAB-62, E-MTAB-37
BT20
2
E-MTAB-37, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC38
2
E-MTAB-37, E-MTAB-62
486 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, E-GEOD-3998, ... (50 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-5099
fibroblast
2
E-GEOD-3204, E-GEOD-3920
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
104 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-MTAB-62, ... (61 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-GEOD-96, E-MTAB-37, E-GEOD-7307
glioblastoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-6014
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
multiple myeloma
3
E-GEOD-6691, E-MTAB-62, E-GEOD-2113
undifferentiated sarcoma
2
E-MEXP-1922, E-MEXP-964
dermatomyositis
2
E-MTAB-62, E-GEOD-1551
248 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (26 experiments)

Factor Value U/D Experiments
none
5
7
E-GEOD-5824, E-TABM-868, E-GEOD-5099, E-GEOD-412, E-TABM-782, ... (12 experiments)
interferon-gamma + lipopolysaccharide
2
E-GEOD-7307, E-GEOD-5099
valproic acid
1
E-GEOD-1615
selenium and vitamin E
1
E-MEXP-1327
TNF
1
E-GEOD-15205
interleukin-20 (Homo sapiens)
1
E-GEOD-7216
36 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-6236, E-MTAB-62

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-1045, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-TABM-127, E-GEOD-20540, E-MEXP-1741, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.528 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM